MAUDE Adverse Event Report: ABBOTT MOLECULAR, INC. ALINITY M SYSTEM; REAL TIME NUCLEIC ACID AMPLIFICATION SYSTEM

Catalog Number	08N53-002
Medical Device Problem Code	Unable to Obtain Readings (1516)
Health Effect - Clinical Code	No Clinical Signs, Symptoms or Conditions (4582)
Date of Event	02/03/2026
Type of Reportable Event	Malfunction
Additional Manufacturer Narrative
Internal studies concluded that the source of cycle number delay can be traced to metal leaching into the lysis solution from the lysis transfer pump in the alinity m system.Impact on product functionality: based on the data summarized in 616-risk, a potential hazard of delay of results was identified for the scenario in which metal leaching in the lysis buffer can lead to invalidated hpv and sti positive assay controls.Without valid controls, the customer will experience a delay in obtaining valid sample results until the troubleshooting is performed to remove the leached metal in the lysis buffer on the instrument.Conclusion: based on the data, the potential hazard associated with this issue is delay in results for the hr hpv and sti assays.There is no potential for incorrect results for the hpv or sti assays.A decision was made to issue a customer letter to notify customers of the reported issue.This field action, fa-am-sep2024-300 was issued on september 12, 2024.Additionally, this action was reported per 21 cfr806 to fda on september 17, 2024 and is recommended to be reported as an fsca (field safety corrective action).For the alinity m hpv assay, complaints associated with metal leaching causing invalidated hpv positive assay controls may be associated with an unacceptable delay in results, which is associated with a minimal severity.For the alinity m sti assay, complaints associated with meal leaching causing invalidated sti positive assay controls, may be associated with an unacceptable delay in results, which is associated with a major severity.See section h10 and list below for complete list of additional mdrs associated with fa-am-sep2024-300: 3005248192-2024-00169 3005248192-2024-00172 3005248192-2024-00173 3005248192-2024-00175 3005248192-2024-00176 3005248192-2024-00177 3005248192-2024-00178 3005248192-2024-00186 3005248192-2024-00200 3005248192-2024-00221 3005248192-2024-00230 3005248192-2025-00039 3005248192-2025-00040 3005248192-2025-00041 3005248192-2025-00062 3005248192-2025-00063 3005248192-2025-00133 3005248192-2025-00135 3005248192-2025-00136 3005248192-2025-00137 3005248192-2025-00138 3005248192-2025-00156 3005248192-2025-00210 3005248192-2025-00211 3005248192-2025-00212 3005248192-2025-00215 3005248192-2025-00239 3005248192-2025-00258 3005248192-2025-00325 3005248192-2025-00338 3005248192-2025-00491 3005248192-2026-00001 3005248192-2026-00002 3005248192-2026-00014 3005248192-2026-00015.
Event or Problem Description
Customer reported that their alinity m sti controls failed for positive control non reactive.Abbott has identified an increase of incidences regarding positive control non reactives while using the alinity m hr hpv amp kit and alinity m sti amp kit.Invalidated positive assay controls can be traced to iron leaching into the alinity m lysis solution from the lysis transfer pump in the alinity m system.There is a potential for non-reactive positive controls to occur while using alinity m hr hpv and alinity m sti amp kits.Metal leaching in the lysis buffer can lead to invalidated hpv and sti positive assay controls.The invalidated patient samples will need to be reprocessed, resulting in a possible delay in result reporting.It has been determined that there is no impact to results generated if valid controls are obtained.No other alinity m assays are impacted.A decision was made to issue a customer letter to notify customers of the reported issue.This field action, fa-am-sep2024-300 was issued on september 12, 2024.Field action was reported per 21cfr806 to us fda via 3005248192-09/12/24-003-c on september 17, 2024.

• Brand Name: ALINITY M SYSTEM
• Common Device Name: REAL TIME NUCLEIC ACID AMPLIFICATION SYSTEM
• Manufacturer (Section D): ABBOTT MOLECULAR, INC.; 1300 e. touhy ave.; des plaines IL 60018 3315
• Manufacturer (Section G): ABBOTT MOLECULAR, INC.; 1300 e. touhy ave.; des plaines IL 60018 3315
• Manufacturer Contact: albert chianello ; 1300 e. touhy ave.; des plaines, IL 60018-3315 ; 2242064064
• MDR Report Key: 24491312
• Report Number: 3005248192-2026-00020
• Device Sequence Number: 14725433
• Product Code: OOI
• UDI-Device Identifier: 00884999048034
• UDI-Public: (01)00884999048034(11)200203(240)08N53-002
• Combination Product (Y/N): N
• Initial Reporter Country: GM
• PMA/510(K) Number: P190025
• Number of Events Summarized: 1
• Summary Report (Y/N): N
• Serviced by Third Party (Y/N): N
• Reporter Type: Manufacturer
• Report Source: Foreign,Health Professional,Company Representative
• Initial Reporter Occupation: Other Health Care Professional
• Remedial Action: Recall
• Type of Report: Initial
• Report Date (Section B): 03/02/2026

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: No
• Is this a Product Problem Report?: Yes
• Operator of Device: Health Professional
• Device Catalogue Number: 08N53-002
• Was Device Available for Evaluation?: Yes
• Is the Reporter a Health Professional?: Yes
• Type of Report(Section G): Thirty-Day
• Initial Date Received by Manufacturer: 02/03/2026
• Initial Report FDA Received Date: 03/02/2026
• Was Device Evaluated by Manufacturer? (Y/N): Yes
• Date Device Manufactured: 02/03/2020
• Is the Device Labeled for Single Use? (Y/N): No
• Is This a Single-Use Device that was Reprocessed and Reused on a Patient? (Y/N): No
• If action reported to FDA under 21 USC 360i(g), list FDA-assigned Recall Number or include a statement: 3005248192-09/12/24-003-
• Patient Sequence Number: 1
• Patient Sex: Unknown